{"id":"vunakizumab-il-17a-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-17A is a key driver of inflammatory and autoimmune responses. By neutralizing IL-17A, vunakizumab reduces the recruitment and activation of immune cells at sites of inflammation, thereby suppressing pathogenic inflammatory cascades. This mechanism is relevant for conditions where IL-17A-mediated inflammation plays a central pathogenic role.","oneSentence":"Vunakizumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in immune-mediated inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:15:59.878Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT07069270","phase":"PHASE2","title":"A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-09-01","conditions":"Vunakizumab, Adebrelimab, Small Cell Lung Cancer","enrollment":28},{"nctId":"NCT06881290","phase":"PHASE1","title":"Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2025-05-19","conditions":"Lupus Erythematosus, Systemic","enrollment":20},{"nctId":"NCT06696417","phase":"","title":"Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis","status":"RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2025-02-17","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":1516},{"nctId":"NCT06779097","phase":"PHASE4","title":"Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-02","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":1564}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vunakizumab (IL-17A inhibitor)","genericName":"Vunakizumab (IL-17A inhibitor)","companyName":"Fujian Cancer Hospital","companyId":"fujian-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vunakizumab is a monoclonal antibody that blocks interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in immune-mediated inflammation. Used for Psoriasis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}